EGFR and cancer: In patients with bladder carcinoma overexpressing EGFR, treatment with an 213Bi-anti-EGFR-MAb-conjugate resulted in satisfactory therapeutic efficacy, showing that in three of 12 patients no signs of carcinoma in situ were present at 3, 30 and 44 months after treatment23.